Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 62.50
Bid: 60.00
Ask: 65.00
Change: 0.00 (0.00%)
Spread: 5.00 (8.333%)
Open: 62.50
High: 62.50
Low: 62.50
Prev. Close: 62.50
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

NetScientific hosts Capital Markets Day

14 Jun 2016 07:00

RNS Number : 0709B
NetScientific PLC
14 June 2016
 

 14 June 2016

 

NetScientific plc

("NetScientific" or the "Group")

 

NetScientific hosts Capital Markets Day to outline its strategy and showcase its portfolio of assets

 

London, UK - 14 June 2016 - NetScientific plc (AIM: NSCI), the transatlantic healthcare technology group, is today hosting a Capital Markets Day in London to outline the comprehensive strategy for the company and provide further detail on its portfolio companies and their path to value creation.

 

Netscientific has undergone a transformation, with a rationalisation of its portfolio and restructuring of the management team, resulting in a streamlined group focused on holding majority positions and delivery and maximising shareholder value from its investments in digital health, diagnostics and therapeutics.

 

At the event in London today, the Company's Chairman, Sir Richard Sykes, and Chief Executive, Francois Martelet, will outline the next steps for NetScientific in maximising value from its portfolio companies. Representatives of the companies will also provide a detailed overview of the companies, the changing landscape in digital health, diagnostics and therapeutics, and their respective strategies for value realisation. The Capital Markets Day will be held at 85 Gresham Street, London EC2V 7NQ, from 12pm until 5pm. The event will conclude with a question and answer session and networking. Presentations from the Capital Markets Day will be made available via the Company's website after the event.

 

Sir Richard Sykes, Chairman of NetScientific, said: "NetScientific's management team and portfolio focus have been totally revitalised under the leadership of Francois Martelet. We now have a focused portfolio of assets which are close to commercialisation and which offer the scope for significant value creation. We look forward to highlighting the key jewels in our crown, and to explaining how they offer opportunities both to provide patient benefit and shareholder value."

 

Presenters at the Netscientific Capital Markets Day will include:

 

· Sir Richard Sykes Chairman, Netscientific

· Francois Martelet CEO, Netscientific

· Gene Walther CEO, Vortex Biosciences

· Steve Curd CEO, Wanda

· Larry Cohen CEO, Glycotest

· Frank K Bedu Addo CEO, PDS Biotechnology

· Dr David Ribeiro CEO, ProAxsis

 

 

 

- Ends -

 

 

 

For more information, please contact:

 

NetScientific

François R. Martelet, M.D., CEO

Ian Postlethwaite, CFO

 

Tel: +44 (0)20 3514 1800

Investec (NOMAD and broker)

Gary Clarence / Daniel Adams

Tel: +44 (0)20 7597 4000

 

Consilium Strategic Communications

Mary-Jane Elliott / Chris Gardner / Jessica Hodgson / Chris Welsh / Laura Thornton

 

Tel: +44 (0)20 3709 5700

netscientific@consilium-comms.com

 

 

 

About NetScientific

NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at www.netscientific.net

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDBGDLSDBBGLX
Date   Source Headline
15th Apr 20247:00 amRNSProAxsis secures c.£1.8mn investment
27th Mar 20241:34 pmRNSPDS Strategy Update and 2023 Financial Results
13th Mar 20247:00 amRNSBusiness Update
5th Feb 20247:00 amRNSExercise of Options and Issue of Shares
23rd Jan 20247:00 amRNSGlycotest secures $1 million investment
1st Dec 20237:00 amRNSDeepTech Recycling secures £1 million investment
14th Nov 20234:39 pmRNSPDS BioTechnology: Third Quarter Results
13th Nov 20237:00 amRNSDirector/PDMR Shareholding
9th Nov 20235:28 pmRNSPDS Biotech Announces Updated Survival Data
6th Nov 20237:00 amRNSVentive secures c.£900,000 investment
2nd Nov 20237:00 amRNSChange of Adviser
23rd Oct 20236:22 pmRNSPDS Preliminary Biomarker Study Results
13th Oct 20237:00 amRNSExercise of Options
3rd Oct 20234:12 pmRNSDirector/PDMR Shareholding
3rd Oct 20233:21 pmRNSPDS: Interim 24-month survival rate of 74% update
3rd Oct 20237:00 amRNSPDS Biotech: new data on PDS0101
28th Sep 20237:00 amRNSInterim Results
13th Sep 20237:00 amRNSQ-Bot: £3.5 million investment to drive expansion
14th Aug 20235:55 pmRNSPDS Biotech: 2nd Quarter Results, Business Update
14th Aug 20235:51 pmRNSPDS Biotech: Submission of Phase 3 Protocol to FDA
3rd Jul 20237:00 amRNSGrant of Options, Issue of Shares, Director/PDMR
30th Jun 20237:00 amRNSDName-iT Holdings Limited Fundraising
29th Jun 202311:04 amRNSResult of AGM & Board Changes
22nd Jun 20237:00 amRNSVortex Fundraising
14th Jun 20233:31 pmRNSPDS Announces Achievement of Efficacy Threshold
7th Jun 20237:00 amRNSDirector/PDMR Shareholding
6th Jun 20237:00 amRNSNotice of AGM
31st May 20237:01 amRNSPreliminary Results for the year ended 31 Dec 2022
31st May 20237:00 amRNSBoard Changes
26th May 20239:39 amRNSPDS Biotech Announces Interim Data
24th May 20237:00 amRNSSofant and Inmarsat announce joint development
15th May 20233:16 pmRNSPDS Business Update and First Quarter Results
2nd May 20237:00 amRNSGlycotest, Inc. Fundraising
3rd Apr 20237:00 amRNSBusiness Update
30th Mar 20233:51 pmRNSPDS Update
28th Mar 20233:50 pmRNSPDS Business Update and 2022 Financial Results
28th Feb 20237:00 amRNSRelated party loan to ProAxsis Limited
27th Feb 20233:28 pmRNSPDS completes FDA meeting for triple combination
10th Feb 20232:05 pmRNSSecond Price Monitoring Extn
10th Feb 20232:00 pmRNSPrice Monitoring Extension
10th Feb 202311:05 amRNSSecond Price Monitoring Extn
10th Feb 202311:00 amRNSPrice Monitoring Extension
1st Feb 20237:00 amRNSBoard Change
3rd Jan 20231:31 pmRNSPDS Announces Exclusive Global License Agreement
28th Dec 20223:05 pmRNSPDS Biotech: Median Overall Survival announcement
16th Dec 20227:00 amRNSPDS: HPV16 Head and Neck Cancer announcement
12th Dec 20222:00 pmRNSBoard Changes; Options; Co-Investment Agreement
29th Nov 20227:00 amRNSEMV C leads £4.2m round in 5G and SATCOM leader
14th Nov 20222:50 pmRNSPDS Q3 Results and Business Update
14th Nov 20222:05 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.